The next big medical breakthrough is on the horizon and all it takes is one idea, one vision, or one conversation for a small, emerging biotech to change the way we treat and cure diseases for generations to come. Recognizing the potential and promise of early-stage companies for addressing unmet…

With thousands of biotech leaders, researchers and entrepreneurs gathering in Philadelphia next week for the 2019 BIO International Convention, Philadelphia native and Spark Therapeutics co-founder and CEO Jeff Marrazzo has penned a new op-ed about the rise of Philadelphia as a hotbed for gene and…

As the biotechnology industry becomes more global, companies must evaluate and adopt various cross-border strategic models to drive capital formation and growth. Reforms within China affecting the biomedical industry, such as the accelerated review and approval of drugs, and the expansion of the…

Despite fifty years of research attempting to develop a solution for a popular health issue, it may take just one new approach to help millions of patients undergoing eye surgery every year. OcuMedic, Inc., the 2018 winner of BIO Convention’s Start-Up Stadium, may have its “starts with one” moment…

The next big medical breakthrough is on the horizon and all it takes is one idea, one vision, or one conversation for a small, emerging biotech to change the way we treat and cure diseases for generations to come. Recognizing the potential and promise of early-stage companies for addressing unmet…

The next big medical breakthrough is on the horizon and all it takes is one idea, one vision, or one conversation for a small, emerging biotech to change the way we treat and cure diseases for generations to come. Recognizing the potential and promise of early-stage companies for addressing unmet…

Most new medicines are developed through a process of collaborative licensing agreements or acquisition. Significant negotiations underlie multiple steps of the R&D lifetime for a medicine and potential partners often repeat within a given therapeutic focus or geographic expansion strategy…

It’s not enough to be a great scientist or entrepreneur with a great idea.  Investors and partners are necessary to support an entrepreneur’s ambition to innovate a medicine that can help patients.  In addition to deal-making skills, storytelling and building value for your company’s…

It took the sequencing of one genome, for a disease that used to mean a death sentence to become treatable and preventable. In 1984, scientists successfully sequenced the entire genome of the HIV virus, a critical first step to understanding and treating the disease. Although researchers may not…

In 1983, patient advocates – now known as the National Organization for Rare Disease, NORD – ignited a movement and rallied support  for the Orphan Drug Act to facilitate development of treatments for conditions affecting fewer than 200,00 Americans.  It started with this one idea and…